Laurence Blumberg,

Laurence (Laur) Blumberg, M.D., MBA is a seasoned life sciences entrepreneur, investor, and executive with more than three decades of experience advancing innovation in biotechnology and healthcare. He has founded, led, and advised multiple successful life-science companies, serving as CEO, COO, President, and Board Director. He is currently working on his next big idea and most recently was President and CEO of Arch Oncology, a clinical-stage immuno-oncology company focused on the CD47 pathway. Previously, he was the founding CEO and President of Syntimmune, which he guided through its $1.2 billion acquisition by Alexion, and co-founder of Syntonix Pharmaceuticals, acquired by Biogen in 2007 which formed the basis of the global $2B hemophilia franchise at Sanofi.

Laur began his career in healthcare equity research and investment management, holding senior roles at Alliance Capital and Blumberg Capital Management.  He currently is an Adjunct Professor lecturing on Entrepreneurship in Life Sciences at Weill Cornell Medicine’s Department of Population Health Sciences.  Laur earned his B.A. in Physics from Brandeis University, M.D. from Temple University School of Medicine, and Executive MBA from Columbia Business School.